Nov 4, 4:01 PM ET
Xencor reported third-quarter 2026 results, with revenue of $116.5 million, up from $21.0 million a year earlier, and net income attributable to Xencor of $39.4 million, or $0.50 per diluted share, compared with a net loss of $6.0 million a year earlier. Revenue came mainly from Alexion and Incyte royalties and a milestone from Astellas, while research and development spending rose, so shareholders should weigh the one-time items behind the profit against higher ongoing development costs.
- Q3 revenue was $116.5 million versus $21.0 million in Q3 2025, driven mainly by royalties from Alexion and Incyte and a milestone from Astellas.
- Q3 net income attributable to Xencor was $39.4 million, or $0.50 per diluted share, versus a net loss of $6.0 million, or $(0.08) per diluted share, a year earlier.
- R&D expenses rose to $84.3 million from $54.4 million, and G&A fell to $9.4 million from $14.2 million, which the company attributed to a non-recurring recovery of legal expenses.
- Cash, cash equivalents and marketable debt securities were $555.7 million at September 30, 2026, and Xencor expects to end 2026 with $480 million to $500 million.
Read the filing on SEC.gov ↗
Oct 26, 7:50 AM ET
Xencor said its current operating plans give it cash to fund research, development and operations into 2029. The company also released updated Phase 1 results for XmAb819 in advanced clear cell renal cell carcinoma, reporting confirmed objective response rates of 30.0% to 45.5% across three dose levels. The data are early and come from small groups, and the filing reports high rates of grade 3 or higher adverse events.
- Cash expected to fund R&D and operations into 2029, based on current operating plans.
- Confirmed objective response rate: 30.0% at 100 μg/kg (n=30), 44.0% at 200 μg/kg (n=25), 45.5% at 400 μg/kg (n=11).
- Grade 3 or higher treatment-emergent adverse events occurred in 82.4% of expansion-dose patients (n=68); one treatment discontinuation due to cytokine release syndrome was reported.
- Full 400 μg/kg analysis expected during 1H 2027 (20+ patients); a potential registration-enabling study is planned to start in 2027.
Read the filing on SEC.gov ↗
Aug 5, 4:01 PM ET
Xencor reported second-quarter 2026 revenue of $51.2 million, up from $43.6 million a year earlier, and a net loss of $21.7 million, or $(0.29) per share, versus a $30.8 million loss, or $(0.41) per share, in the same period of 2025. The quarter included $27.6 million of royalty revenue from a settlement with Alexion, and the company expects to end 2026 with $420 million to $440 million in cash and marketable debt securities, down from $610.8 million at December 31, 2025.
- Q2 2026 revenue was $51.2 million versus $43.6 million in Q2 2025; it included $27.6 million of Alexion settlement royalty revenue.
- Net loss attributable to Xencor was $21.7 million, or $(0.29) per share, versus $30.8 million, or $(0.41) per share, a year earlier.
- Research and development expenses rose to $71.9 million from $61.7 million, while other income, net, was $15.1 million, largely from unrealized gains on an equity security.
- Cash, cash equivalents and marketable debt securities were $486.4 million at June 30, 2026; year-end 2026 guidance is $420 million to $440 million.
Read the filing on SEC.gov ↗
Jul 29, 4:05 PM ET
Xencor entered a settlement agreement with Alexion that resolves a dispute over U.S. royalties on Ultomiris, with Xencor to receive $105 million in two equal payments. Alexion will have no further obligation to pay royalties on U.S. sales, while ex-U.S. royalties are unchanged. Xencor said that, based on current operating plans, it expects cash to fund research and development programs and operations through 2028.
- Total payment of $105 million, in two $52.5 million installments
- First $52.5 million payment anticipated in August 2026; second payment due within 14 days after the one-year anniversary of the agreement
- Alexion has no further obligation to pay royalties on U.S. sales of Ultomiris; ex-U.S. royalties are unchanged
- Cash runway expected through 2028; year-end 2026 cash guidance to be updated with second-quarter 2026 results
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.